Clinical Trials

Clinical Trial Detail

Return to search results.

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Complete title: A Phase 1/2 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies

Research Study Number       2724.00
    
Principal Investigator       Bill Bensinger, MD
    
Phase       I

Look up trial at NIH

Research Study Description

Primary Objective:

- To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984

Secondary Objectives:

- To characterize the global safety profile including cumulative toxicities

- To evaluate the pharmacokinetic (PK) profile of SAR650984 in the proposed dosing schedule(s)

- To assess the pharmacodynamics, immune response, and preliminary disease response

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       2724.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Hematologic Malignancies

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.